Hospital
H H Health System-Morgan LLC
H H Health System-Morgan LLC was paid $6.88M by Medicaid between Jan 2018 and Nov 2024, across 120 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoH H HEALTH SYSTEM-MORGAN LLC
DECATUR, AL 35601
DECATUR, AL 35601
33aNPI1356692297assigned 10/01/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.88M
24GClaims317,432
24DCodes billed120
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#8 of 77
Median peer was paid$1.13M
This provider vs. median6.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,767 | $692K | |
| 2019 | 50,699 | $793K | |
| 2020 | 34,712 | $536K | |
| 2021 | 49,264 | $830K | |
| 2022 | 52,897 | $1.16M | |
| 2023 | 54,714 | $1.89M | |
| 2024incomplete | 29,379 | $981K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 24,349 | 22,594 | $1.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 35,445 | 33,003 | $1.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 4,317 | 3,909 | $1.21M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 11,932 | 11,015 | $437K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.3% | 8,825 | 8,216 | $368K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.6% | 27,697 | 16,557 | $313K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 33,222 | 29,981 | $258K |
| 80053 | Comprehensive metabolic panel | 3.6% | 26,025 | 23,686 | $246K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 11,267 | 10,184 | $115K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 2,705 | 2,305 | $110K |
| 87430 | 1.4% | 6,410 | 6,043 | $98K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.3% | 3,183 | 2,962 | $89K |
108 more codes
| 81001 | <1% | 19,922 | $67K | |
| 87088 | <1% | 6,803 | $63K | |
| 87081 | <1% | 5,479 | $52K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 662 | $46K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,821 | $35K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,644 | $31K |
| 87807 | <1% | 2,353 | $30K | |
| 80061 | Lipid panel | <1% | 1,940 | $29K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 9,897 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,641 | $29K |
| 81025 | <1% | 8,898 | $28K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,156 | $24K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,113 | $23K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 185 | $22K |
| 87070 | <1% | 1,907 | $21K | |
| 83735 | <1% | 2,572 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,513 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 342 | $17K |
| 84484 | <1% | 2,640 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,273 | $13K |
| 83690 | <1% | 2,102 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,420 | $13K |
| 84480 | <1% | 648 | $12K | |
| 84439 | <1% | 1,158 | $12K | |
| 83525 | <1% | 1,152 | $12K | |
| 83880 | <1% | 507 | $11K | |
| 83721 | <1% | 1,171 | $8K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $7K |
| 86762 | <1% | 356 | $7K | |
| 80305 | <1% | 794 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 91 | $6K |
| 86803 | <1% | 358 | $6K | |
| 0002A | <1% | 162 | $6K | |
| 86592 | <1% | 1,119 | $6K | |
| 83655 | <1% | 344 | $5K | |
| 0001A | <1% | 180 | $5K | |
| 82607 | <1% | 249 | $5K | |
| 83605 | <1% | 597 | $5K | |
| 87340 | <1% | 361 | $5K | |
| 83020 | <1% | 286 | $5K | |
| 83021 | <1% | 280 | $4K | |
| 82550 | <1% | 797 | $4K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 320 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 192 | $3K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 40 | $3K |
| 81003 | <1% | 1,172 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 116 | $3K |
| 86850 | <1% | 455 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 518 | $2K |
| 86140 | <1% | 1,200 | $2K | |
| 85610 | <1% | 554 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 44 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 57 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 173 | $2K |
| 86900 | <1% | 513 | $1K | |
| 80076 | <1% | 207 | $1K | |
| 86901 | <1% | 513 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,981 | $1K |
| 85027 | <1% | 271 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,448 | $1K |
| 83540 | <1% | 124 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 30 | $887.68 |
| 85730 | <1% | 442 | $885.55 | |
| 82948 | <1% | 279 | $844.14 | |
| 74022 | <1% | 44 | $837.21 | |
| 82077 | <1% | 104 | $834.21 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 513 | $826.99 |
| 85379 | <1% | 96 | $709.24 | |
| 82150 | <1% | 132 | $661.74 | |
| 84100 | <1% | 150 | $595.80 | |
| 93017 | <1% | 60 | $561.20 | |
| 85018 | <1% | 157 | $468.45 | |
| 85014 | <1% | 140 | $416.40 | |
| 83550 | <1% | 28 | $374.34 | |
| 84702 | <1% | 36 | $364.56 | |
| 72110 | <1% | 20 | $318.36 | |
| 84481 | <1% | 22 | $271.92 | |
| 87040 | <1% | 49 | $262.86 | |
| 59025 | Fetal non-stress test | <1% | 77 | $256.28 |
| 87186 | <1% | 32 | $222.42 | |
| 82728 | <1% | 15 | $207.20 | |
| 87077 | <1% | 32 | $197.56 | |
| 73562 | <1% | 13 | $188.79 | |
| 86800 | <1% | 21 | $179.78 | |
| 72050 | <1% | 14 | $169.74 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 445 | $127.32 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,774 | $86.76 |
| 82465 | <1% | 12 | $76.92 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 103 | $66.62 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 16 | $53.90 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16 | $25.68 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 27 | $19.76 |
| 93041 | <1% | 15 | $17.79 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 116 | $4.48 |
| 80353 | 0% | 550 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 1,202 | $0.00 |
| 80358 | 0% | 550 | $0.00 | |
| 80324 | 0% | 549 | $0.00 | |
| 80345 | 0% | 550 | $0.00 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 990 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 260 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 129 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 169 | $0.00 |
| 80361 | 0% | 550 | $0.00 | |
| 80346 | 0% | 550 | $0.00 | |
| 80365 | 0% | 550 | $0.00 | |
| 83992 | 0% | 550 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBONETTI, VINCENT (EXECUTIVE DIRECTOR, REVENUE CYCLE)
Parent organizationH H HEALTH SYSTEMS-MORGAN LLC
| Provider | Location | Paid |
|---|---|---|
| HH Health System - Shoals LLC | Sheffield, AL | $4.99M |
| HH Health System - Shoals LLC | Red Bay, AL | $176K |
| Medexpress Red Bay LLC | Red Bay, AL | $7K |
| Decatur General Hospital | Decatur, AL | $6K |
| Medexpress Littleville LLC | Russellville, AL | $5K |
| H H Health System-Morgan LLC | Decatur, AL | $328.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.